Press Releases Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
3.82 ^USD	+4.09%		+1.60%	+25.30%

05-03	Aileron Therapeutics Closes Direct Offering of Shares, Warrants	MT
05-01	Transcript : Aileron Therapeutics, Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aileron Therapeutics to Present at Two Upcoming Investor Conferences	05-06	AQ
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million	05-03	AQ
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million	05-01	AQ
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)	05-01	AQ
Aileron Therapeutics : Corporate Presentation April 2024	04-15	PU
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	04-15	AQ
Aileron Therapeutics : Management Change/Compensation - Form 8-K	03-29	PU
Aileron Therapeutics Announces CEO Transition	03-12	AQ
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event	02-15	AQ
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024	02-01	AQ
Aileron Therapeutics : Merger Announcement	31/10/23	PU
Aileron Therapeutics Announces Acquisition of Lung Therapeutics	31/10/23	PR
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/05/23	AQ
AILERON THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	20/03/23	AQ
AILERON THERAPEUTICS INC : Costs Associated with Exit or Disposal Activities, Other Events (form 8-K)	23/02/23	AQ
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives	21/02/23	AQ
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements	30/11/22	AQ
AILERON THERAPEUTICS INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	10/11/22	AQ
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split	10/11/22	GL
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split	10/11/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Press Releases

Filters